Anaplastic Lymphoma Kinase (ALK) Inhibitors (SJ-08-0025)
Technology Name
(St. Jude Reference #) |
Anaplastic Lymphoma Kinase (ALK) Inhibitors
(SJ-08-0025) |
| Description |
ALK is a receptor tyrosine kinase that has been associated with several different cancers. Researchers at St. Jude have designed, synthesized and tested a novel kinase inhibitor template. Compounds based on this core template demonstrate activity and selectivity for ALK, indicating they are suitable starting points for the development of more active lead-like inhibitors. |
| Keywords |
NPM-ALK, kinase, lymphoma, cancer, inhibitor |
| Granted Patents or Published Applications |
Pending provisional application |
| Related Scientific References |
Slavish P. Jake et al; Design and synthesis of a novel tyrosine kinase inhibitor template; Bioorganic & Medicinal Chemistry 17 (2009) 3308 – 3316. |
| Licensing Opportunities |
We are currently seeking licensing opportunities in all fields for this technology. |
|
|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2009